• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症相关突变如何影响p53四聚化结构域的寡聚化状态?

How Do Cancer-Related Mutations Affect the Oligomerisation State of the p53 Tetramerisation Domain?

作者信息

Nicolini Federica, Todorovski Toni, Puig Eduard, Díaz-Lobo Mireia, Vilaseca Marta, García Jesús, Andreu David, Giralt Ernest

机构信息

Institute for Research in Biomedicine (IRB Barcelona), Baldiri Reixac 10, 08028 Barcelona, Spain.

Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain.

出版信息

Curr Issues Mol Biol. 2023 Jun 7;45(6):4985-5004. doi: 10.3390/cimb45060317.

DOI:10.3390/cimb45060317
PMID:37367066
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10296842/
Abstract

Tumour suppressor p53 plays a key role in the development of cancer and has therefore been widely studied in recent decades. While it is well known that p53 is biologically active as a tetramer, the tetramerisation mechanism is still not completely understood. p53 is mutated in nearly 50% of cancers, and mutations can alter the oligomeric state of the protein, having an impact on the biological function of the protein and on cell fate decisions. Here, we describe the effects of a number of representative cancer-related mutations on tetramerisation domain (TD) oligomerisation defining a peptide length that permits having a folded and structured domain, thus avoiding the effect of the flanking regions and the net charges at the - and -terminus. These peptides have been studied under different experimental conditions. We have applied a variety of techniques, including circular dichroism (CD), native mass spectrometry (MS) and high-field solution NMR. Native MS allows us to detect the native state of complexes maintaining the peptide complexes intact in the gas phase; the secondary and quaternary structures were analysed in solution by NMR, and the oligomeric forms were assigned by diffusion NMR experiments. A significant destabilising effect and a variable monomer population were observed for all the mutants studied.

摘要

肿瘤抑制蛋白p53在癌症发展中起关键作用,因此在近几十年中受到了广泛研究。虽然众所周知p53作为四聚体具有生物学活性,但其四聚化机制仍未完全阐明。在近50%的癌症中p53发生了突变,这些突变会改变蛋白质的寡聚状态,进而影响蛋白质的生物学功能以及细胞命运的决定。在此,我们描述了一些具有代表性的癌症相关突变对四聚化结构域(TD)寡聚化的影响,确定了一个允许形成折叠和结构化结构域的肽长度,从而避免侧翼区域以及N端和C端净电荷的影响。这些肽已在不同实验条件下进行了研究。我们应用了多种技术,包括圆二色性(CD)、基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)和高场溶液核磁共振(NMR)。基质辅助激光解吸电离飞行时间质谱使我们能够检测复合物的天然状态,在气相中保持肽复合物完整无损;通过核磁共振在溶液中分析二级和四级结构,并通过扩散核磁共振实验确定寡聚形式。对于所有研究的突变体,均观察到了显著的去稳定作用和可变的单体群体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/7c51f4b0c716/cimb-45-00317-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/f96e97d4a8e9/cimb-45-00317-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/2555923bb357/cimb-45-00317-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/17c643781abd/cimb-45-00317-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/5fee6b23d63a/cimb-45-00317-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/7c51f4b0c716/cimb-45-00317-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/f96e97d4a8e9/cimb-45-00317-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/2555923bb357/cimb-45-00317-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/17c643781abd/cimb-45-00317-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/5fee6b23d63a/cimb-45-00317-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe1/10296842/7c51f4b0c716/cimb-45-00317-g005.jpg

相似文献

1
How Do Cancer-Related Mutations Affect the Oligomerisation State of the p53 Tetramerisation Domain?癌症相关突变如何影响p53四聚化结构域的寡聚化状态?
Curr Issues Mol Biol. 2023 Jun 7;45(6):4985-5004. doi: 10.3390/cimb45060317.
2
Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein.四聚化对p53位点特异性翻译后修饰的影响:人源和鼠源p53肿瘤抑制蛋白的比较
Cancer Biol Ther. 2008 Sep;7(9):1481-9. doi: 10.4161/cbt.7.9.6473. Epub 2008 Sep 18.
3
Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability.人p53四聚化结构域的串联二聚化稳定了初级二聚体中间体,并显著增强了其寡聚稳定性。
J Mol Biol. 2007 Jan 26;365(4):1217-31. doi: 10.1016/j.jmb.2006.10.051. Epub 2006 Oct 21.
4
Influence of the N-terminal region on the oligomerisation between human and Xenopus laevis p53.N 端区域对人和非洲爪蟾 p53 之间寡聚化的影响。
J Mol Biol. 1999 May 21;288(5):883-90. doi: 10.1006/jmbi.1999.2734.
5
Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor.p53肿瘤抑制因子四聚体寡聚化结构域结构稳定性的热力学分析
Biochemistry. 1995 Apr 25;34(16):5309-16. doi: 10.1021/bi00016a002.
6
The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.小鼠p53肿瘤抑制蛋白的N端是一个影响激活和热稳定性的独立调节结构域。
J Mol Biol. 1998 Jan 30;275(4):575-88. doi: 10.1006/jmbi.1997.1507.
7
In vitro structure-function analysis of the beta-strand 326-333 of human p53.人p53蛋白β链326 - 333的体外结构-功能分析
J Mol Biol. 1997 Nov 7;273(4):873-81. doi: 10.1006/jmbi.1997.1360.
8
p53 mutants without a functional tetramerisation domain are not oncogenic.没有功能性四聚化结构域的p53突变体不具有致癌性。
J Mol Biol. 1999 Mar 12;286(5):1269-74. doi: 10.1006/jmbi.1999.2563.
9
Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification头部损伤的转化代谢组学:基于体外核磁共振波谱的代谢物定量分析探索脑代谢功能障碍
10
p53: an overview of over two decades of study.p53:二十多年研究综述
Malays J Pathol. 2001 Jun;23(1):9-16.

引用本文的文献

1
Correlation of p53 oligomeric status and its subcellular localization in the presence of the AML-associated NPM mutant.在急性髓系白血病相关的核仁磷酸蛋白(NPM)突变存在的情况下,p53寡聚状态与其亚细胞定位的相关性。
PLoS One. 2025 May 7;20(5):e0322096. doi: 10.1371/journal.pone.0322096. eCollection 2025.

本文引用的文献

1
Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program.二聚体 p53 突变通过改变代谢程序发挥独特的肿瘤抑制活性。
Cancer Discov. 2023 May 4;13(5):1230-1249. doi: 10.1158/2159-8290.CD-22-0872.
2
The role of truncated p53 isoforms in the DNA damage response.截断型 p53 异构体在 DNA 损伤反应中的作用。
Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188882. doi: 10.1016/j.bbcan.2023.188882. Epub 2023 Mar 26.
3
Targeting p53 pathways: mechanisms, structures, and advances in therapy.
靶向 p53 通路:机制、结构和治疗进展。
Signal Transduct Target Ther. 2023 Mar 1;8(1):92. doi: 10.1038/s41392-023-01347-1.
4
Structural Basis of Mutation-Dependent p53 Tetramerization Deficiency.突变依赖的 p53 四聚体缺陷的结构基础。
Int J Mol Sci. 2022 Jul 19;23(14):7960. doi: 10.3390/ijms23147960.
5
Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study.探究癌症相关 R337H 突变导致 p53TD 四聚体不稳定的机制:分子动力学研究。
Phys Chem Chem Phys. 2022 Feb 23;24(8):5199-5210. doi: 10.1039/d1cp05670k.
6
Deciphering the PTM codes of the tumor suppressor p53.解析肿瘤抑制因子 p53 的 PTM 密码。
J Mol Cell Biol. 2022 Jan 21;13(11):774-785. doi: 10.1093/jmcb/mjab047.
7
The Common Germline Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model.常见的种系突变是功能不全的,并在小鼠模型中导致不完全外显和肿瘤晚期发生。
Cancer Res. 2021 May 1;81(9):2442-2456. doi: 10.1158/0008-5472.CAN-20-1750. Epub 2021 Feb 26.
8
The complex architecture of p53 binding sites.p53 结合位点的复杂结构。
Nucleic Acids Res. 2021 Feb 22;49(3):1364-1382. doi: 10.1093/nar/gkaa1283.
9
What 20 years of research has taught us about the TP53 p.R337H mutation.20 年研究揭示 TP53 p.R337H 突变的奥秘。
Cancer. 2020 Nov 1;126(21):4678-4686. doi: 10.1002/cncr.33143. Epub 2020 Aug 17.
10
p53 tetramerization: at the center of the dominant-negative effect of mutant p53.p53 四聚体化:突变型 p53 显性负效应的中心。
Genes Dev. 2020 Sep 1;34(17-18):1128-1146. doi: 10.1101/gad.340976.120.